ENTRATA: CB-839 in Renal Cell Carcinoma
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

ENTRATA: CB-839 in Renal Cell Carcinoma

Sponsor: Calithera Biosciences, Inc.

Protocol CX-839-005: A placebo controlled study of CB-839 plus everolimus verses placebo plus everolimus in patients with a clear cell renal cell carcinoma that have previously been treated with anti- PD1/PDL1 therapy and a VEGFR targeting tyrosine kinase inhibitor.